Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.
Vilclagliptin is a competitive and reversible inhibitor of dipeptidyl peptidase-4. Dipeptidyl peptidase-4 inhibitors act mainly by preventing the rapid degradation of glucagon-like peptide-1. In clinical trials, vildagliptin improves glycaemic control both as monotherapy and in combination with metformin for periods of :! 52 weeks in subjects with Type 2 diabetes. This is evident by reduced fastin